Profile data is unavailable for this security.
About the company
Hypera SA, formerly Hypermarcas SA, is a Brazil-based company engaged in the pharmaceuticals sector. The Company’s major business units include Branded Prescription, Consumer Health and Branded Generics. Branded Prescription is present in the main therapeutic classes in Brazil and it operates in the Primary Care segment under the umbrella brand Mantecorp Farmasa. The Branded Prescription unit also acts as Mantecorp Skincare in dermocosmetics, with products recommended by dermatologists. Consumer Health offers non-prescription drugs, with brands such as Apracur, Benegrip, Coristina d, Engov, Epocler and Estomazil, among others. The Consumer Health unit also operates in nutritionals and vitamin supplements, with brands such as Tamarine, Vitasay, Biotonico Fontoura and Zero-Cal. Branded Generics operates under the Neo Quimica brand.
- Revenue in BRL (TTM)8.04bn
- Net income in BRL1.70bn
- Incorporated2001
- Employees9.00k
- LocationHypera SARua Nova Cidade, 404, Vila OlimpiaSAO PAULO 04.547-070BrazilBRA
- Phone+55 1 136274206
- Fax+55 1 136274371
- Websitehttps://www.hypera.com.br/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADMA Biologics Inc | 1.58bn | -20.39m | 17.24bn | 624.00 | -- | 20.04 | 646.01 | 10.88 | -0.0204 | -0.0204 | 1.23 | 0.6632 | 0.8188 | 0.9923 | 7.44 | 453,808.40 | -1.05 | -24.80 | -1.21 | -28.00 | 40.13 | 17.40 | -1.29 | -51.31 | 1.86 | 2.19 | 0.4598 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Xiamen Amoytop Biotech Co Ltd | 1.71bn | 461.93m | 17.60bn | 1.96k | 38.10 | 11.40 | -- | 10.27 | 1.48 | 1.48 | 5.47 | 4.93 | 1.04 | 0.8541 | 6.70 | 1,135,877.00 | 28.09 | 17.96 | 32.72 | 21.02 | 93.17 | 90.48 | 26.95 | 19.17 | 3.22 | -- | 0.0037 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
| Virbac SA | 7.59bn | 738.44m | 18.02bn | 5.46k | 24.38 | 3.25 | 17.60 | 2.37 | 14.36 | 14.36 | 147.65 | 107.57 | 0.894 | 1.30 | 7.94 | 228,412.00 | 8.65 | 8.70 | 12.12 | 12.44 | 64.93 | 65.61 | 9.67 | 10.21 | 1.08 | 18.05 | 0.1166 | 7.21 | 2.53 | 7.49 | -0.5289 | 43.26 | 12.08 | -- |
| Hypera SA | 8.04bn | 1.70bn | 18.23bn | 9.00k | 10.78 | 1.56 | 9.33 | 2.27 | 2.67 | 2.67 | 12.60 | 18.50 | 0.3366 | 1.34 | 3.19 | -- | 7.13 | 8.29 | 8.64 | 9.98 | 62.47 | 63.49 | 21.18 | 26.01 | 1.37 | -- | 0.4798 | 50.18 | 4.88 | 16.27 | -3.30 | 7.74 | 29.83 | 10.24 |
| Twist Bioscience Corp | 1.55bn | -1.08bn | 18.32bn | 919.00 | -- | 5.84 | -- | 11.80 | -3.35 | -3.35 | 4.83 | 9.63 | 0.3565 | 4.87 | 7.04 | 301,943.40 | -24.68 | -30.50 | -27.12 | -33.84 | 38.29 | 36.02 | -69.24 | -113.33 | 5.06 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 2.33bn | 369.35m | 18.75bn | 5.10k | 51.45 | 9.60 | 40.60 | 8.05 | 35.13 | 35.13 | 221.51 | 188.36 | 0.9232 | 2.53 | 5.52 | -- | 14.64 | 15.77 | 18.04 | 18.89 | 66.07 | 62.03 | 15.86 | 16.06 | 1.56 | 17.11 | 0.1144 | 32.31 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
| HUTCHMED (China) Ltd | 4.69bn | 563.95m | 19.07bn | 1.99k | 34.04 | 4.67 | 31.18 | 4.07 | 0.8974 | 0.8974 | 7.61 | 6.55 | 0.7258 | 7.19 | 7.69 | 3,292,181.00 | 8.76 | -14.35 | 13.36 | -20.43 | 54.12 | 36.57 | 12.06 | -31.44 | 2.60 | -- | 0.1038 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
| Ajanta Pharma Ltd | 2.81bn | 545.48m | 19.07bn | 7.84k | 35.27 | 8.07 | 29.99 | 6.78 | 64.79 | 64.79 | 334.10 | 283.31 | 0.9034 | 1.30 | 3.65 | 5,365,515.00 | 17.52 | 16.61 | 22.41 | 20.47 | 74.66 | 73.22 | 19.39 | 19.31 | 2.12 | -- | 0.0098 | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
Data as of Jul 22 2024. Currency figures normalised to Hypera SA's reporting currency: Brazilian Real BRL
24.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BV Distribuidora de T�tulos e Valores Mobili�rios Ltda.as of 09 Apr 2024 | 32.40m | 5.12% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 29.44m | 4.65% |
| Capital International Ltd.as of 30 Jun 2024 | 19.85m | 3.13% |
| Fidelity Management & Research Co. LLCas of 31 May 2024 | 18.41m | 2.91% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 15.34m | 2.42% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 12.06m | 1.90% |
| UBS Asset Management (Singapore) Ltd.as of 31 Mar 2024 | 7.43m | 1.17% |
| MFS International (UK) Ltd.as of 31 May 2024 | 7.25m | 1.14% |
| Vontobel Asset Management AGas of 28 Jun 2024 | 6.03m | 0.95% |
| BTG Pactual WM Gest�o de Recursos Ltda.as of 31 Mar 2024 | 5.00m | 0.79% |
More ▼
Data from 31 Mar 2024 - 31 May 2024Source: FactSet Research Systems Inc.
